Psychotic symptoms are common in Alzheimer’s disease (AD) and related neurodegenerative disorders and are associated with more rapid disease progression and increased mortality. It is unclear to what degree existing criteria are utilized in clinical research and practice.
Objective:
To establish research criteria for the diagnosis of psychosis in AD.
Methods:
The International Society to Advance Alzheimer’s Research and Treatment (ISTAART) Neuropsychiatric Symptoms (NPS) Professional Interest Area (PIA) psychosis subgroup reviewed existing criteria for psychosis in AD and related dementias. Through a series of in person and on-line meetings, a priority checklist was devised to capture features necessary for current research and clinical needs. PubMed, Medline and other relevant databases were searched for relevant criteria.
Results:
Consensus identified three sets of criteria suitable for review including those of Jeste and Finkel, Lyketsos, and the Diagnostic and Statistical Manual for Mental Disorders, 5th edition. It was concluded that existing criteria could be augmented by including a more specific differentiation between delusions and hallucinations, address overlap with related conditions (agitation in particular), adding the possibility of symptoms emerging in the preclinical and prodromal phases, and building on developing research in disease biomarkers.
Conclusion:
We propose criteria, developed to improve phenotypic classification of psychosis in AD, and advance the research agenda in the field to improve epidemiological, biomarker, and genetics research in the field. These criteria serve as a complement to the International Psychogeriatric Association criteria for psychosis in neurocognitive disorders.
RopackiSA, JesteDV (2005) Epidemiology of and risk factors for psychosis of Alzheimer’s disease: A review of 55 studies published from 1990 to 2003. Am J Psychiatry162, 2022–2030.
3.
JesteDV, FinkelSI (2000) Psychosis of Alzheimer’s disease and related dementias. Diagnostic criteria for a distinct syndrome. Am J Geriatr Psychiatry8, 29–34.
4.
LyketsosCG, BreitnerJC, RabinsPV (2001) An evidence-based proposal for the classification of neuropsychiatric disturbance in Alzheimer’s disease. Int J Geriatr Psychiatry16, 1037–1042.
5.
American Psychiatric Association (3013) Diagnostic and statistical manual of mental disorders: DSM-5. American Psychiatric Association, Washington, DC.
6.
EmanuelJE, LopezOL, HouckPR, BeckerJT, WeamerEA, Demichele-SweetMA, KullerL, SweetRA (2011) Trajectory of cognitive decline as a predictor of psychosis in early Alzheimer disease in the cardiovascular health study. Am J Geriatr Psychiatry19, 160–168.
7.
ConnorsMH, AmesD, WoodwardM, BrodatyH (2018) Psychosis and clinical outcomes in Alzheimer disease: A longitudinal study. Am J Geriatr Psychiatry26, 304–313.
8.
BassionyMM, SteinbergMS, WarrenA, RosenblattA, BakerAS, LyketsosCG (2000) Delusions and hallucinations in Alzheimer’s disease: Prevalence and clinical correlates. Int J Geriatr Psychiatry15, 99–107.
9.
ScarmeasN, BrandtJ, AlbertM, HadjigeorgiouG, PapadimitriouA, DuboisB, SarazinM, DevanandD, HonigL, MarderK, BellK, WegesinD, BlackerD, SternY (2005) Delusions and hallucinations are associated with worse outcome in Alzheimer disease. Arch Neurol62, 1601–1608.
10.
WilsonRSTY, AggarwalNT, GilleyDW, MccannJJ, BieniasJL, EvansDA (2006) Hallucinations, cognitive decline, and death in Alzheimer’s disease. Neuroepidemiology26, 68–75.
11.
PoirierA, VoyerP, LégaréF, MorinM, WittemanHO, KrögerE, MartineauB, RodríguezC, GiguereAM (2017) Caring for seniors living with dementia means caring for their caregivers too. Can J Public Health108, e639–e642.
12.
FischerCE, SweetRA (2016) Psychosis in Alzheimer’s disease: A review of recent research findings. Curr Behav Neurosci Rep3, 308–317.
13.
PetersME, SchwartzS, HanD, RabinsPV, SteinbergM, TschanzJT, LyketsosCG (2015) Neuropsychiatric symptoms as predictors of progression to severe Alzheimer’s dementia and death: The Cache County Dementia Progression Study. Am J Psychiatry172, 460–465.
14.
FischerCE, Aguera-OrtizL (2018) Psychosis and dementia: Risk factor, prodrome, or cause?Int Psychogeriatr30, 209–219.
15.
PorsteinssonAP, DryeLT, PollockBG, DevanandDP, FrangakisC, IsmailZ, MaranoC, MeinertCL, MintzerJE, MunroCA, PeltonG, RabinsPV, RosenbergPB, SchneiderLS, ShadeDM, WeintraubD, YesavageJ, LyketsosCG, CitAD Research Group (2014) Effect of citalopram on agitation in Alzheimer disease: The CitAD randomized clinical trial. JAMA311, 682–691.
16.
RibeAR, LaursenTM, CharlesM, KatonW, Fenger-GronM, DavydowD, ChwastiakL, CerimeleJM, VestergaardM (2015) Long-term risk of dementia in persons with schizophrenia: A Danish population-based cohort study. JAMA Psychiatry72, 1095–1101.
17.
KuH, LeeEK, LeeKU, LeeMY, KwonJW (2016) Higher prevalence of dementia in patients with schizophrenia: A nationwide population-based study. Asia Pac Psychiatry8, 145–153.
18.
PurohitDP, PerlDP, HaroutunianV, PowchikP, DavidsonM, DavisKL (1998) Alzheimer disease and related neurodegenerative diseases in elderly patients with schizophrenia: A postmortem neuropathologic study of 100 cases. Arch Gen Psychiatry55, 205–211.
19.
HeatonRK, GladsjoJA, PalmerBW, KuckJ, MarcotteTD, JesteDV (2001) Stability and course of neuropsychological deficits in schizophrenia. Arch Gen Psychiatry58, 24–32.
20.
JesteDV, WolkowitzOM, PalmerBW (2011) Divergent trajectories of physical, cognitive, and psychosocial aging in schizophrenia. Schizophr Bull37, 451–455.
21.
TingC, RajjiTK, IsmailZ, Tang-WaiDF, ApanasiewiczN, MirandaD, MamoD, MulsantBH (2010) Differentiating the cognitive profile of schizophrenia from that of Alzheimer disease and depression in late life. PLoS One5, e10151.
22.
DrangeOK, SmelandOB, ShadrinAA, FinsethPI, WitoelarA, FreiO, Psychiatric Genomics Consortium Bipolar Disorder Working Group, WangY, HassaniS, DjurovicS, DaleAM, AndreassenOA (2019) Genetic overlap between Alzheimer’s disease and bipolar disorder implicates the MARK2 and VAC14 genes. Front Neurosci13, 220.
23.
WuKY, ChangCM, LiangHY, WuCS, Chia-Hsuan WuE, ChenCH, ChauYL, TsaiHJ (2013) Increased risk of developing dementia in patients with bipolar disorder: A nested matched case-control study. Bipolar Disord15, 787–794.
24.
AlmeidaOP, McCaulK, HankeyGJ, YeapBB, GolledgeJ, FlickerL (2016) Risk of dementia and death in community-dwelling older men with bipolar disorder. Br J Psychiatry209, 121–126.
25.
DinizBS, TeixeiraAL, CaoF, GildengersA, SoaresJC, ButtersMA, ReynoldsCF3rd (2017) History of bipolar disorder and the risk of dementia: A systematic review and meta-analysis. Am J Geriatr Psychiatry25, 357–362.
26.
IsmailZ, GatchelJ, BatemanDR, Barcelos-FerreiraR, ChantillonM, JaegerJ, DonovanNJ, MortbyME (2018) Affective and emotional dysregulation as pre-dementia risk markers: Exploring the mild behavioral impairment symptoms of depression, anxiety, irritability, and euphoria. Int Psychogeriatr30, 185–196.
27.
FischerCE, TingWK, MillikinCP, IsmailZ, SchweizerTA, Alzheimer Disease Neuroimaging Initiative (2016) Gray matter atrophy in patients with mild cognitive impairment/Alzheimer’s disease over the course of developing delusions. Int J Geriatr Psychiatry31, 76–82.
28.
FischerCE, QianW, SchweizerTA, IsmailZ, SmithEE, MillikinCP, MunozDG (2017) Determining the impact of psychosis on rates of false-positive and false-negative diagnosis in Alzheimer’s disease. Alzheimers Dement (N Y)3, 385–392.
29.
GedaYE, SchneiderLS, GitlinLN, MillerDS, SmithGS, BellJ, EvansJ, LeeM, PorsteinssonA, LanctôtKL (2013) Neuropsychiatric symptoms in Alzheimer’s disease: Past progress and anticipation of the future. Alzheimers Dement9, 602–608.
IsmailZ, SmithEE, GedaY, SultzerD, BrodatyH, SmithG, Aguera-OrtizL, SweetR, MillerD, LyketsosCG, ISTAART Neuropsychiatric Symptoms Professional Interest Area (2016) Neuropsychiatric symptoms as early manifestations of emergent dementia: Provisional diagnostic criteria for mild behavioral impairment. Alzheimers Dement12, 195–202.
32.
American Psychiatric Association (1994) Diagnostic Criteria From DSM-IV, American Psychiatric Association, Washington, DC.
33.
IsmailZ, NguyenMQ, FischerCE, SchweizerTA, MulsantBH, MamoD (2011) Neurobiology of delusions in Alzheimer’s disease. Curr Psychiatry Rep13, 211–218.
34.
SchneiderLS, KatzIR, ParkS, NapolitanoJ, MartinezRA, AzenSP (2003) Psychosis of Alzheimer disease: Validity of the construct and response to risperidone. Am J Geriatr Psychiatry11, 414–425.
35.
LaughrenT, GordonM (2000) FDA background on Zeldox (ziprasidone hydrochloride capsules). Pfizer, Inc. Psychopharmacological Drugs Advisory Committee. July 19, 2000.
36.
LyketsosCG, LopezO, JonesB, FitzpatrickAL, BreitnerJ, DeKoskyS (2002) Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: Results from the cardiovascular health study. JAMA288, 1475–1483.
37.
Van der MusseleS, MariënP, SaerensJ, SomersN, GoemanJ, De DeynPP, EngelborghsS (2015) Psychosis associated behavioral and psychological signs and symptoms in mild cognitive impairment and Alzheimer’s dementia. Aging Ment Health19, 818–828.
38.
ChanDC, KasperJD, BlackBS, RabinsPV (2003) Prevalence and correlates of behavioral and psychiatric symptoms in community-dwelling elders with dementia or mild cognitive impairment: The Memory and Medical Care Study. Int J Geriatr Psychiatr18, 174–182.
39.
GallagherD, FischerCE, IaboniA (2017) Neuropsychiatric symptoms in mild cognitive impairment: An update on prevalence, mechanisms, and clinical significance. Can J Psychiatry62, 161–169.
40.
DietlinS, SotoM, KiyasovaV, PueyoM, de MauleonA, DelrieuJ, OussetPJ, VellasB (2019) Neuropsychiatric symptoms and risk of progression to Alzheimer’s disease among mild cognitive impairment subjects. J Alzheimers Dis70, 25–34.
41.
LyketsosCG, SheppardJM, SteinbergM, TschanzJA, NortonMC, SteffensDC, BreitnerJC (2001) Neuropsychiatric disturbance in Alzheimer’s disease clusters into three groups: The Cache County study. Int J Geriatr Psychiatry16, 1043–1053.
42.
IsmailZ, EmeremniCA, HouckPR, MazumdarS, RosenJ, RajjiTK, PollockBG, MulsantBH (2013) A comparison of the E-BEHAVE-AD, NBRS, and NPI in quantifying clinical improvement in treatment of agitation and psychosis associated with dementia. Am J Geriatr Psychiatry21, 78–87.
GedaYE, SmithGE, KnopmanDS, BoeveBF, TangalosEG, IvnikRJ, MrazekDA, EdlandSD, PetersenRC (2004) De novo genesis of neuropsychiatric symptoms in mild cognitive impairment (MCI). Int Psychogeriatr16, 51–60.
45.
KotrlaKJ, ChackoRC, HarperRG, DoodyR (1995) Clinical variables associated with psychosis in Alzheimer’s disease. Am J Psychiatry152, 1377–1379.
46.
CookSE, MiyaharaS, BacanuS-A, Perez-MadriñanG, LopezOL, KauferDI, NimgaonkarVL, WisniewskiSR, DeKoskyST, SweetRA (2003) Psychotic symptoms in Alzheimer disease: Evidence for subtypes. Am J Geriatr Psychiatry11, 406–413.
47.
QianW, FischerCE, SchweizerTA, MunozDG (2018) Association between psychosis phenotype and APOE genotype on the clinical profiles of Alzheimer’s disease. Curr Alzheimer Res15, 187–194.
48.
HowardR, RabinsPV, SeemanMV, JesteDV (2000) Late-onset schizophrenia and very-late-onset schizophrenia-like psychosis: An international consensus. The International Late-Onset Schizophrenia Group. Am J Psychiatry157, 172–178.
49.
LeroiI, VoulgariA, BreitnerJC, LyketsosCG (2003) The epidemiology of psychosis in dementia. Am J Geriatr Psychiatry11, 83–91.
50.
KimJ, SchweizerTA, FischerCE, MunozDG (2018) Psychosis in “cognitively asymptomatic” elderly subjects is associated with neuritic plaque load, not neurofibrillary tangles. Alzheimer Dis Assoc Disord32, 185–189.
51.
BallardC, McKeithI, HarrisonR, ObrienJ, ThompsonP, LoweryK, PerryR, InceP (1997) A detailed phenomenological comparison of complex visual hallucinations in dementia with Lewy bodies and Alzheimer’s disease. Int Psychogeriatr9, 381–388.
52.
FfytcheDH, PereiraJB, BallardC, ChaudhuriKR, WeintraubD, AarslandD (2017) Risk factors for early psychosis in PD: Insights from the Parkinson’s progression markers initiative. J Neurol Neurosurg Psychiatry88, 325–331.
53.
ErskineD, TaylorJP, ThomasA, CollertonD, McKeithI, KhundakarA, AttemsJ, MorrisC (2019) Pathological changes to the subcortical visual system and its relationship to visual hallucinations in dementia with Lewy bodies. Neurosci Bull35, 295–300.
DucharmeS, BajestanS, DickersonBC, VoonV (2017) Psychiatric presentations of C9orf72 mutation: What are the diagnostic implications for clinicians?J Neuropsychiatry Clin Neurosci29, 195–205.
56.
DevenneyEM, AhmedRM, HallidayG, PiguetO, KiernanMC, HodgesJR (2018) Psychiatric disorders in C9orf72 kindreds: Study of 1,414 family members. Neurology91, e1498–e1507.
57.
TogoT, IsojimaD, AkatsuH, SuzukiK, UchikadoH, KatsuseO, IsekiE, KosakaK, HirayasuY (2005) Clinical features of argyrophilic grain disease: A retrospective survey of cases with neuropsychiatric symptoms. Am J Geriatr Psychiatry13, 1083–1091.
58.
FörstlH, BurnsA, LevyR, CairnsN (1994) Neuropathological correlates of psychotic phenomena in confirmed Alzheimer’s disease. Br J Psychiatry165, 53–59.
59.
WatersF, CollertonD, FfytcheDH, JardriR, PinsD, DudleyR, BlomJD, MosimannUP, EperjesiF, FordS, LaroiF (2014) Visual hallucinations in the psychosis spectrum and comparative information from neurodegenerative disorders and eye disease. Schizophr Bull40 Suppl 4, S233–245.
60.
CohenCI, MeestersPD, ZhaoJ (2015) New perspectives on schizophrenia in later life: Implications for treatment, policy, and research. Lancet Psychiatry2, 340–350.
61.
SeppäläTT, LouhijaUM, AppelbergB, HerukkaSK, JuvaK (2014) Comparison between clinical diagnosis and CSF biomarkers of Alzheimer disease in elderly patients with late onset psychosis: Helsinki old age psychosis study (HOPS). Am J Geriatr Psychiatry22, 908–916.
62.
Vilalta-FranchJ, Lopez-PousaS, Calvo-PerxasL, Garre-OlmoJ (2013) Psychosis of Alzheimer disease: Prevalence, incidence, persistence, risk factors, and mortality. Am J Geriatr Psychiatry21, 1135–1143.
63.
HauptM, KurzA, JännerM (2000) A 2-year follow-up of behavioural and psychological symptoms in Alzheimer’s disease. Dement Geriatr Cogn Disord11, 147–152.
64.
BallardCGSK, PatelA, GahirM, SolisM, CoopeB, WilcockG (1995) The prevalence and phenomenology of psychotic symptoms in dementia sufferers. Int J Geriatr Psychiatr10, 477–485.
65.
DevanandDP, JacobsDM, TangMX, Del Castillo-CastanedaC, SanoM, MarderK, BellK, BylsmaFW, BrandtJ, AlbertM, SternY (1997) The course of psychopathologic features in mild to moderate Alzheimer disease. Arch Gen Psychiatry54, 257–263.
66.
BallardCG, O’BrienJT, SwannAG, ThompsonP, NeillD, McKeithIG (2001) The natural history of psychosis and depression in dementia with Lewy bodies and Alzheimer’s disease: Persistence and new cases over 1 year of follow-up. J Clin Psychiatry62, 46–49.
67.
ReevesSJ, GouldRL, PowellJF, HowardRJ (2012) Origins of delusions in Alzheimer’s disease. Neurosci Biobehav Rev36, 2274–2287.
68.
BruenPD, McGeownWJ, ShanksMF, VenneriA (2008) Neuroanatomical correlates of neuropsychiatric symptoms in Alzheimer’s disease. Brain131, 2455–2463.
69.
LeeYM, ChungYI, ParkJM, LeeBD, MoonE, JeongHJ, KimJH, KimHJ, MunCW, KimTH, KimYH, KimEJ (2016) Decreased gray matter volume is associated with the subtypes of psychotic symptoms in patients with antipsychotic-naive mild or moderate Alzheimer’s disease: A voxel-based morphometry study. Psychiatry Res Neuroimaging249, 45–51.
70.
NakaakiS, SatoJ, ToriiK, OkaM, NegiA, NakamaeT, NarumotoJ, MiyataJ, FurukawaTA, MimuraM (2013) Neuroanatomical abnormalities before onset of delusions in patients with Alzheimer’s disease: A voxel-based morphometry study. Neuropsychiatr Dis Treat9, 1–8.
71.
SerraL, PerriR, CercignaniM, SpanoB, FaddaL, MarraC, CarlesimoGA, CaltagironeC, BozzaliM (2010) Are the behavioral symptoms of Alzheimer’s disease directly associated with neurodegeneration?J Alzheimers Dis21, 627–639.
72.
MatsuokaT, NarumotoJ, ShibataK, OkamuraA, NakamuraK, OkuyamaC, NishimuraT, FukuiK (2010) Insular hypoperfusion correlates with the severity of delusions in individuals with Alzheimer’s disease. Dement Geriatr Cogn Disord29, 287–293.
73.
MoranEK, BeckerJA, SatlinA, LyooIK, FischmanAJ, JohnsonKA (2008) Psychosis of Alzheimer’s disease: Gender differences in regional perfusion. Neurobiol Aging29, 1218–1225.
74.
NakatsukaM, MeguroK, TsuboiH, NakamuraK, AkanumaK, YamaguchiS (2013) Content of delusional thoughts in Alzheimer’s disease and assessment of content-specific brain dysfunctions with BEHAVE-AD-FW and SPECT. Int Psychogeriatr25, 939–948.
75.
SultzerDL, LeskinLP, MelroseRJ, HarwoodDG, NarvaezTA, AndoTK, MandelkernMA (2014) Neurobiology of delusions, memory, and insight in Alzheimer disease. Am J Geriatr Psychiatry22, 1346–1355.
76.
IsmailZ, NguyenMQ, FischerCE, SchweizerTA, MulsantBH (2012) Neuroimaging of delusions in Alzheimer’s disease. Psychiatry Res202, 89–95.
77.
JellingerKA (2012) Cerebral correlates of psychotic syndromes in neurodegenerative diseases. J Cell Mol Med16, 995–1012.
78.
RosenbergPB, NowrangiMA, LyketsosCG (2015) Neuropsychiatric symptoms in Alzheimer’s disease: What might be associated brain circuits?Mol Aspects Med43-44, 25–37.
79.
QianW, SchweizerTA, ChurchillNW, MillikinC, IsmailZ, Smith EE5 LixLM, MunozDG, BarfettJJ, RajjiTK, FischerCE (2018) Grey matter changes associated with the development of delusions in Alzheimer’s disease. Am J Geriatr Psychiatry27, 490–498.
CummingsJ, IsaacsonS, MillsR, WilliamsH, Chi-BurrisK, CorbettA, DhallR, BallardC (2014) Pimavanserin for patients with Parkinson’s disease psychosis: A randomised, placebo-controlled phase 3 trial. Lancet383, 533–540.
82.
BallangerB, StrafellaAP, van EimerenT, ZurowskiM, RusjanPM, HouleS, FoxSH (2010) Serotonin 2A receptors and visual hallucinations in Parkinson disease. Arch Neurol67, 416–421.
83.
BlinJ, BaronJC, DuboisB, CrouzelC, FiorelliM, Attar-LévyD, PillonB, FournierD, VidailhetM, AgidY (1993) Loss of brain 5-HT2 receptors in Alzheimer’s disease In vivo assessment with positron emission tomography and [18F]setoperone. Brain116, 497–510.
84.
JaakkolaE, JoutsaJ, MakinenE, JohanssonJ, KaasinenV (2017) Ventral striatal dopaminergic defect is associated with hallucinations in Parkinson’s disease. Eur J Neurol24, 1341–1347.
85.
ReevesS, McLachlanE, BertrandJ, AntonioFD, BrowningsS, NairA, GreavesS, SmithA, TaylorD, DunnJ, MarsdenP, KesslerR, HowardR (2017) Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer’s disease. Brain140, 1117–1127.
86.
ZhengXDF, BarmadaMM, RichardsonGA, LopezOL, SweetRA (2014) A rare duplication on chromosome 16p11.2 is identified in patients with psychosis in Alzheimer’s disease. PLoS One9, e111462.
87.
HollingworthP, HamshereML, HolmansPA, O’DonovanMC, SimsR, PowellJ, LovestoneS, MyersA, DeVriezeFW, HardyJ, GoateA, OwenM, WilliamsJ (2007) Increased familial risk and genomewide significant linkage for Alzheimer’s disease with psychosis. Am J Med Genet B Neuropsychiatr Genet144B, 841–848.
88.
CreeseB, VassosE, BerghS, AthanasiuL, JoharI, RongveA, MedbøenIT, Vasconcelos Da SilvaM, AakhusE, AndersenF, BettellaF, BraekhusA, DjurovicS, ParoniG, ProitsiP, SaltvedtI, SeripaD, StordalE, FladbyT, AarslandD, AndreassenOA, BallardC, SelbaekGAddNeuroMed consortium and the Alzheimer’s Disease Neuroimaging Initiative (2019) Examining the association between genetic liability for schizophrenia and psychotic symptoms in Alzheimer’s disease. Transl Psychiatry9, 273.
89.
SweetRA, NimgaonkarVL, DevlinB, LopezOL, DeKoskyST (2002) Increased familial risk of the psychotic phenotype of Alzheimer disease. Neurology58, 907–911.
90.
SweetRA, BennettDA, Graff-RadfordNR, MayeuxR, National institute on aging late-onset Alzheimer’s disease family study group (2010) Assessment and familial aggregation of psychosis in Alzheimer’s disease from the National Institute on Aging Late Onset Alzheimer’s Disease Family Study. Brain133, 1155–1162.
91.
DeMichele-SweetMA, SweetRA (2010) Genetics of psychosis in Alzheimer’s disease: A review. J Alzheimers Dis19, 761–780.
92.
KoppelJ, SundayS, ButhornJ, GoldbergT, DaviesP, GreenwaldB, Alzheimer’s Disease Neuroimaging Initiative (2013) Elevated CSF Tau is associated with psychosis in Alzheimer’s disease. Am J Psychiatry170, 1212–1213.
93.
KrivinkoJM, EricksonSL, DingY, SunZ, PenzesP, MacDonaldML, YatesNA, IkonomovicMD, LopezOL, SweetRA, KoflerJ (2019) Synaptic proteome compensation and resilience to psychosis in Alzheimer’s disease. Am J Psychiatry175, 999–1009.
94.
PaquetC, MagninE, WallonD, TroussiereAC, DumurgierJ, JagerA, BellivierF, Bouaziz-AmarE, BlancF, BeaufilsE, Miguet-AlfonsiC, QuillardM, SchraenS, PasquierF, HannequinD, RobertP, HugonJ, Mouton-LigerF, For ePLM network and collaborators (2016) Utility of CSF biomarkers in psychiatric disorders: A national multicentre prospective study. Alzheimers Res Ther8, 27.
95.
FischerCE, QianW, SchweizerTA, MillikinCP, IsmailZ, SmithEE, LixLM, SheltonP, MunozDG (2016) Lewy bodies, vascular risk factors, and subcortical arteriosclerotic leukoencephalopathy, but not Alzheimer pathology, are associated with development of psychosis in Alzheimer’s disease. J Alzheimers Dis50, 283–295.
